<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705341</url>
  </required_header>
  <id_info>
    <org_study_id>ALAACRC07</org_study_id>
    <nct_id>NCT00705341</nct_id>
  </id_info>
  <brief_title>MethaCholine Bronchoprovocation Study (MeCIS)</brief_title>
  <acronym>MeCIS</acronym>
  <official_title>MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Long Island Jewish Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the methacholine challenge test as an accurate
      indicator of asthma in patients receiving treatment for asthma. Phase 1 on the study compares
      methacholine challenge test results from asthma patients to those from people who do not have
      asthma. In phase 2, test results for people with asthma on low dose inhaled corticosteroid
      will be compared to results on high dose inhaled corticosteroids. Both males and females with
      stable asthma (asthma participants) and without asthma (controls) enrolled. Participants will
      be between 12 and 69 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two phases. The first phase is a cross-sectional, case-control study
      measuring the sensitivity and specificity of methacholine challenge testing for
      differentiating asthmatic participants from non-asthmatic controls. The second phase is a
      cross-over, randomized, double-masked trial designed to evaluate the impact of high dose
      versus low dose inhaled corticosteroids (ICS) on bronchial hyperreactivity (BHR) in
      asthmatics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methacholine Challenge Test Result for Phase 2</measure>
    <time_frame>weeks 0, 4</time_frame>
    <description>Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test post-diluent baseline (PC20) after medication holds; PC20 is the methacholine dose at which the amount of air expired in the first second during a forced expiratory maneuver is reduced by 20%; value represents change in baseline to 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive Value of Methacholine Challenge Test for Phase 1</measure>
    <time_frame>one time</time_frame>
    <description>Predictive value of methacholine challenge test in phase 1 for asthmatics and nonasthmatic controls</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Low dose fluticasone for phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For people with asthma, fluticasone at 250 mcg per day; phase 2 of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose fluticasone for phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonasthmatic controls for phase 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthmatic controls for phase 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone</intervention_name>
    <description>Inhaled corticosteroid approved for treatment of asthma</description>
    <arm_group_label>Low dose fluticasone for phase 2</arm_group_label>
    <arm_group_label>High dose fluticasone for phase 2</arm_group_label>
    <other_name>Flovent diskus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Asthmatic participants

        Inclusion Criteria:

          -  Males or females greater than or equal to 12 and less than 70 years of age

          -  Physician-diagnosed and investigator-confirmed stable asthma (excluding exercise
             induced asthma)

          -  Current treatment for asthma by a healthcare provider within the preceding twelve
             months: current asthma treatment defined as regular use of asthma medications. Asthma
             medications include short and long acting adrenergic bronchodilators, bronchodilator
             combinations, inhaled anticholinergics, inhaled corticosteroids, cromolyn sodium and
             nedocromil, leukotriene modifiers and methylxanthines

          -  Stable asthma defined by no asthma exacerbation (emergency room visit,
             hospitalization, course of increased systemic steroids, or urgent health care visit
             for asthma) during the prior four weeks

          -  Forced expiratory volume at one second (FEV1) &gt;70% predicted pre-bronchodilator

          -  Ability to provide screening and baseline information

          -  Ability and willingness to provide informed consent

          -  For women of childbearing potential: not pregnant, non-lactating, and agree to
             practice an adequate birth control method (abstinence, combination barrier and
             spermicide, or hormonal) for the duration of the study

        Exclusion Criteria:

          -  Chronic oral steroid therapy (daily)

          -  Oral corticosteroid use within past 4 weeks

          -  Respiratory tract infection within past 4 weeks

          -  Chronic diseases (other than asthma) that in the opinion of the investigator would
             prevent participation in the trial or put the participant at risk by participation,
             e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, or
             nervous system, or immunodeficiency

          -  Known allergy to methacholine (for example, a previous bad reaction to methacholine)
             or to any other parasympathomimetic agents

          -  Current use of beta adrenergic blocking agent (a heart medicine) or a cholinesterase
             inhibitor (medicine used to treat myasthenia gravis or Alzheimer's disease).

          -  History of epilepsy, cardiovascular disease with bradycardia (slow heart beat),
             vagotonia (increased activity of the vagus nerve causing slow heart rate or low blood
             pressure), peptic ulcer disease, thyroid disease, or urinary tract obstruction

          -  History of cigarette smoking within the past 5 years or &gt;10 pack years total

          -  Use of investigative drugs or intervention trials in the 30 days prior to enrollment
             or during the duration of the study

          -  Any condition or compliance issue which in the opinion of the investigator might
             interfere with participation

        Nonasthmatic control criteria:

        Inclusion Criteria:

          -  Males or females greater than or equal to 12 and less than 70 years of age

          -  Individuals who are in good overall health

          -  Age (within ten years for above 25 years of age and +/- five years for 12-25 years of
             age) and sex matched to the asthmatic group

        Exclusion Criteria:

          -  A subject will be excluded if there is a history within the previous 5 years of:

               -  clinically diagnosed allergy (allergic rhinitis, hay fever or atopic dermatitis),

               -  asthma (beyond 6 years of age),

               -  chronic nasal or sinus disease, or

               -  other chronic lung diseases

          -  Respiratory tract infection within past 4 weeks

          -  History of cigarette smoking within the past 5 years or &gt;10 pack years total

          -  Known allergy to methacholine (for example, a previous bad reaction to methacholine)
             or to any other parasympathomimetic agents

          -  Current use of beta adrenergic blocking agent (a heart medicine) or a cholinesterase
             inhibitor (medicine used to treat myasthenia gravis or Alzheimer's disease).

          -  History of epilepsy, cardiovascular disease with bradycardia (slow heart beat),
             vagotonia (increased activity of the vagus nerve causing slow heart rate or low blood
             pressure), peptic ulcer disease, thyroid disease, or urinary tract obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaharu Sumino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Asthma Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Univestiy of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisianna State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri-Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>631110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Consortium/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at the University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cctrials.org/alaacrc</url>
    <description>Asthma Clinical Research Centers website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>August 1, 2012</results_first_submitted>
  <results_first_submitted_qc>February 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Janet Holbrook</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Normal Controls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asthmatic Controls for Phase 1</title>
          <description>People with asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
        </group>
        <group group_id="P2">
          <title>Non Asthmatic Controls for Phase 1</title>
          <description>People without asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
        </group>
        <group group_id="P3">
          <title>Low Dose, Then High Dose Fluticasone for Phase 2</title>
          <description>People with asthma receive fluticasone at 250 mcg per day (28 days), then wash-out period (28 days), then fluticasone at 1000 mcg per day (28 days) in phase 2.</description>
        </group>
        <group group_id="P4">
          <title>High Dose, Then Low Dose Fluticasone for Phase 2</title>
          <description>People with asthma receive fluticasone at 1000 mcg per day 28 days), then wash-out period (28 days), fluticasone at 250 mcg per day (28 days) in phase 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1:Control Challenge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126">If participants in this group met criteria, they were randomized into phase 2</participants>
                <participants group_id="P2" count="93">Nonasthmatic controls did not advance to phase 2 due to design of study</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2: Trial</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="30">This group was randomized from asthmatic controls in phase 1 if they met criteria to be in phase 2</participants>
                <participants group_id="P4" count="32">This group was randomized from asthmatic controls in phase 1 if they met criteria to be in phase 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet post-diluent threshold</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nonasthmatic Controls for Phase 1</title>
          <description>People without asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
        </group>
        <group group_id="B2">
          <title>Asthmatic Controls for Phase 1</title>
          <description>People with asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="13"/>
                    <measurement group_id="B2" value="38" spread="15"/>
                    <measurement group_id="B3" value="35" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methacholine Challenge Test Result for Phase 2</title>
        <description>Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test post-diluent baseline (PC20) after medication holds; PC20 is the methacholine dose at which the amount of air expired in the first second during a forced expiratory maneuver is reduced by 20%; value represents change in baseline to 4 weeks</description>
        <time_frame>weeks 0, 4</time_frame>
        <population>There was a significant period effect in the percentage change in post diluent baseline (PC20) for high- and low-dose depending upon the order in which the doses were administered. In order to remove the effect of the order, we compared the high- and low-dose MCT results exclusively during the first cross over.</population>
        <group_list>
          <group group_id="O1">
            <title>4 Weeks of High Dose Fluticasone</title>
            <description>4 weeks of Fluticasone (Flovent diskus) 500 mcg twice daily (1000mcg/day)</description>
          </group>
          <group group_id="O2">
            <title>4 Weeks of Low Dose Fluticasone</title>
            <description>4 weeks of Fluticasone (Flovent diskus) 250 mcg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Methacholine Challenge Test Result for Phase 2</title>
          <description>Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test post-diluent baseline (PC20) after medication holds; PC20 is the methacholine dose at which the amount of air expired in the first second during a forced expiratory maneuver is reduced by 20%; value represents change in baseline to 4 weeks</description>
          <population>There was a significant period effect in the percentage change in post diluent baseline (PC20) for high- and low-dose depending upon the order in which the doses were administered. In order to remove the effect of the order, we compared the high- and low-dose MCT results exclusively during the first cross over.</population>
          <units>mg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.10" upper_limit="26.92"/>
                    <measurement group_id="O2" value="2.04" lower_limit="0.16" upper_limit="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log-linear generalized estimating equation (GEE) models were used to assess the dose effect on PC20.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictive Value of Methacholine Challenge Test for Phase 1</title>
        <description>Predictive value of methacholine challenge test in phase 1 for asthmatics and nonasthmatic controls</description>
        <time_frame>one time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asthmatic Controls for Phase 1</title>
            <description>People with asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
          </group>
          <group group_id="O2">
            <title>Non Asthmatic Controls for Phase 1</title>
            <description>People without asthma perform 1 methacholine challenge test in phase 1 to measure the sensitivity and specificity of methacholine challenge testing. Participants did not receive an intervention in phase 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Predictive Value of Methacholine Challenge Test for Phase 1</title>
          <description>Predictive value of methacholine challenge test in phase 1 for asthmatics and nonasthmatic controls</description>
          <units>% predictive value</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                    <measurement group_id="O2" value="75" lower_limit="66" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected in phase 1 of the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose for phase1</title>
          <description>4 weeks of Fluticasone (Flovent diskus) 250 mcg twice daily (500 mcg/day)</description>
        </group>
        <group group_id="E2">
          <title>High Dose for Phase 2</title>
          <description>4 weeks of Fluticasone (Flovent diskus) 500 mcg twice daily (1000mcg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort and pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hoarseness/ dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Viral lower respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Viral gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory inflammation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Capser</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-8183</phone>
      <email>ashankli@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

